secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001639691-24-000006
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova approves restructuring plan, winds down ACS unit; expects ~$110M impairment in Q4 2023
--------------------------------------------------------------------------------

- Board approved restructuring to focus on Cardiopulmonary and Neuromodulation; wind down ACS unit by end of 2024.
- Pre-tax restructuring charges of $15M-$20M in 2024, including $10M-$12M severance/retention and $5M-$8M other expenses.
- Triggering event in Q4 2023 leads to pre-tax non-cash impairment charge up to $110M, primarily for finite-lived intangibles.
- Some ACS products transitioned to Cardiopulmonary; LifeSPARC and Hemolung systems to be discontinued by end of 2024.
- Company to realign into two reportable segments: Cardiopulmonary and Neuromodulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/0001639691-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969124000006/livn-20240105.htm
  HTML page:      https://secwatch.observer/filing/0001639691-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer